ArticleBehavioral and brain functions : BBF2026
The role of the kynurenine pathway in conditioned place aversion induced by synthetic cannabinoid CP-55940.
Article in Behavioral and brain functions : BBF, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe therapeutic potential of cannabinoids is increasingly recognized; however, their use is often associated with adverse effects, such as conditioned place aversion (CPA). The molecular mechanisms underlying CPA remain poorly understood, particularly the role of the kynurenine pathway (KP) and its interaction with cannabinoid receptors. This study aimed to elucidate these mechanisms, focusing on the synthetic.
methodsWe employed a mouse conditioned place preference behavioral model to assess CPA following the administration of CP-55940 at a dosage of 1 mg/kg via intraperitoneal injection. We conducted a comprehensive analysis of key metabolites in the kynurenine pathway, specifically measuring levels of kynurenic acid (KYNA) in the hippocampus, while also monitoring quinolinic acid levels for comparison. Additionally, we utilized pharmacological inhibition of KATII with PF-04859989 to further explore KYNA’s role in mediating CPA.
resultsOur findings revealed significant increases in tryptophan, kynurenine, and KYNA levels in the hippocampus following administration of CP-55940, whereas quinolinic acid levels remained unchanged. Notably, pharmacological inhibition of KATII effectively reduced CPA, thereby affirming the critical role of KYNA in the aversive response. Furthermore, we observed that KYNA downregulated CB1 receptor (CB1R) expression, which was restored upon inhibition of KYNA synthesis. Additionally, G protein-coupled receptor 35 (GPR35) expression was significantly reduced in the CPA model, and its levels were positively correlated with KYNA, suggesting intricate molecular interactions.
conclusionThis study elucidates the complex interplay between KYNA, CB1R, and GPR35 in the context of cannabinoid-induced CPA, highlighting the pivotal role of the TRP–KYN pathway in mediating adverse behavioral effects associated with cannabinoids. These findings open avenues for the development of therapeutic targets aimed at mitigating such effects. Future research should focus on validating these results through gene knockout models and further exploring the clinical implications of KYNA modulation in cannabinoid pharmacology and neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.